Scynexis Obtains Milestone Payment In Merial Research Collaboration

Scynexis has received a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005. Scynexis, focuses considerable medicinal chemistry, advanced biological screening, bioanalytical and Admet efforts towards Merial’s animal health discovery efforts.

Peter Hanson, head of pharmaceutical R&D at Merial, said: “Merial is excited about the continued success of our pharmaceutical discovery program. Together with Scynexis we have reached another milestone in our program that focuses on designing novel compounds that specifically address animal health needs.”

Yves Ribeill, president and CEO of Scynexis, said: “Scynexis is pleased to have reached another important milestone in the discovery of animal health solutions with our valued partner Merial. The achievement of this milestone, which is the third associated with the agreement, demonstrates Scynexis’ ability to bring innovation to the animal health pharmaceutical area.”